Immunomodulation and preeclampsia.
Immune system
Inflammation
NK cell
PLGF
Preeclampsia
VEGF
Journal
Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
07
03
2019
revised:
10
04
2019
accepted:
17
06
2019
pubmed:
18
7
2019
medline:
18
2
2020
entrez:
18
7
2019
Statut:
ppublish
Résumé
Preeclampsia (PE) is an enigmatic syndrome, still with unknown aetiology and multi-factorial pathogenesis. Our understanding of the role of the immune system in PE development has undergone a transformation over the years. From a model based on the alterations in cell-mediated immunity, research moved on to a vision centred on the alteration of the humoural immunity and on the systemic involvement of the inflammatory system. The first hypothesis was classically derived from the evidence that an adequate maternal immunological response is necessary in pregnancy to allow the survival of the foetus. An abnormal response of the maternal immune system against the placenta may be the first pathogenetic step of PE, followed by a systemic inflammatory reaction. Currently available treatments for PE are mainly preventative with aspirin. Treatment aims to modulate inflammation and the immune system before their changes become established.
Identifiants
pubmed: 31311760
pii: S1521-6934(19)30084-7
doi: 10.1016/j.bpobgyn.2019.06.005
pii:
doi:
Substances chimiques
Placenta Growth Factor
144589-93-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-96Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.